Ticker Details
Aurinia Pharmaceuticals Inc Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.
IPO Date:	September 1, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.9B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.23 | 2.67%
Avg Daily Range (30 D):	$0.18 | 1.24%
Avg Daily Range (90 D):	$0.23 | 1.60%

Institutional Daily Volume
Avg Daily Volume:	1.72M
Avg Daily Volume (30 D):	.7M
Avg Daily Volume (90 D):	1.04M

Trade Size
Avg Trade Size (Sh.):	166
Avg Trade Size (Sh.) (30 D):	64
Avg Trade Size (Sh.) (90 D):	75

Institutional Trades
Total Institutional Trades:	2,599
Avg Institutional Trade:	$1.29M
Avg Institutional Trade (30 D):	$1.57M
Avg Institutional Trade (90 D):	$2.04M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.35M
Avg Closing Trade (30 D):	$1.46M
Avg Closing Trade (90 D):	$1.77M
Avg Closing Volume:	128.81K

News

Jan 8, 2025 @ 8:35 PM New American College of Rheumatology Guidelines fo... Source: Spherix Global Insights

Oct 2, 2024 @ 1:48 PM Corporate and Individual Donations Provide Much-Ne... Source: American Kidney Fund

Jun 17, 2024 @ 8:46 AM Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump... Source: Zacks Equity Research

May 7, 2024 @ 1:55 PM How Much Upside is Left in Aurinia (AUPH)? Wall St... Source: Zacks Equity Research

May 2, 2024 @ 11:10 AM Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, To... Source: Zacks Equity Research

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS		$.24	$.16
Diluted EPS		$.23	$.16
Revenue		$73.47M	$70.01M
Gross Profit		$65.29M	$62.89M
Net Income / Loss		$31.55M	$21.51M
Operating Income / Loss		$29.75M	$20.08M
Cost of Revenue		$8.18M	$7.12M
Net Cash Flow		$20.19M	$-13.43M
PE Ratio

Splits
Oct 23, 2013	1:50